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Abstract
Background: Anti-TNF agents have revolutionised rheumatoid arthritis (RA) treatment; however, a third of patients
fail to achieve therapeutic responses. Unexpectedly, studies in murine and human arthritis have indicated that
anti-TNF treatment can increase circulating T helper 17 (Th17) cells, but the relationship to treatment response is
unclear. To identify immune correlates of anti-TNF treatment response, we conducted a longitudinal study using
clinical, ultrasound and T cell assessments.
Methods: Patients with RA (n = 25) were studied at protocol visits during the initial 12 weeks of anti-TNF treatment.
Improvement in the disease activity score of 28 joints (DAS28) >1.2 defined treatment responders (n = 16) and
non-responders (n = 9). Changes in synovial thickening and vascularity of 10 metacarpophalangeal joints were
quantitatively assessed by grey scale and power Doppler ultrasound. The frequency of circulating Th17 cells was
determined by IL17 enzyme-linked immunospot assay (Elispot) and flow cytometry (fluorescence-activated cell
sorting (FACS)).
Results: The frequency of circulating IL17-producing cells increased significantly 12 weeks after anti-TNF initiation
(Elispot median (range) specific spot forming cells (spSFC)/106 360 (280–645) vs 632 (367 − 1167), p = 0.003).
The increase in CD4 + IL17+ cells at 12 weeks was confirmed by FACS (median (range) %, 0.7 (0.5–0.9) vs 1.05
(0.6–1.3); p = 0.01). The increase in circulating Th17 cells inversely correlated with reduction in synovial vascularity
(r = -0.68, p = 0.007) and thickening (r = -0.39; p = 0.04). Higher frequencies of circulating Th17 cells at baseline were
associated with poorer anti-TNF treatment response defined by ultrasonographic measures.
Conclusions: These results demonstrate a link between changes in circulating Th17 cells with resolution of
ultrasonographic features of synovial inflammation and vascularity during anti-TNF treatment. The findings may
reflect redistribution of Th17 cells from inflamed joints or TNF-driven regulation of Th17 cell production.
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Background
Th17 cells are a highly pro-inflammatory T helper (Th)
cell subset, which have been shown to contribute to
arthritis pathogenesis [1, 2]. Their signature cytokine,
interleukin 17 (IL-17), has pleiotropic effects on effector
cells of the immune system and can induce production
of other pro-inflammatory cytokines [1], contribute to
cartilage damage by promoting release of matrix metal-
loproteinases, increase osteoclast differentiation leading
to bony erosions and mediate angiogenesis in inflamed
joints [2–5]. Increased frequencies of Th17 cells and
IL17 levels have been found in the peripheral blood of
patients with RA compared to healthy controls or pa-
tients with osteoarthritis. In addition, Th17 cells are fur-
ther enriched in RA synovial fluid and tissue, where
their levels correlate with inflammatory markers and ac-
tive synovitis [6–9]. Histological studies have also shown
the presence of IL17 in T-cell-rich areas of synovium [3, 6].
Furthermore, synovial tissue IL17 mRNA has been shown
to be associated with increased progression of joint damage
in RA in a 2-year prospective study [10].
Anti-TNF treatment has revolutionised the manage-
ment of RA, leading to improvement in signs and symp-
toms, and slowing progression identified on radiography
[11]. However, despite anti-TNF treatment being suc-
cessful in the majority of patients, 20–30% of patients do
not respond or experience significant side effects [12].
Assessing RA disease activity is critically important to be
able to adjust treatment regimens with the aim being to
‘treat to target’ and achieve low disease activity or induce
remission, and in the long term prevent joint damage
[13]. Power Doppler ultrasound (PDUS) has become an
invaluable tool for this as multiple studies have demon-
strated its increased sensitivity in the detection of syn-
ovial inflammation compared with clinical examination
alone [14–17]. Moreover, PDUS has been shown to be
more sensitive than clinical outcome measures in evalu-
ating treatment response [18–22]. Specifically, PDUS
scores have been shown to reflect changes in disease ac-
tivity during anti-TNF treatment in patients with RA,
and reduced scores following therapy are associated with
reduced progression of joint damage [19, 22]. However,
no data are available to date to investigate the impact of
anti-TNF therapy on T cell subsets in RA in relation to
changes in synovial thickening and vascularity in the
joints.
In collagen-induced arthritis (CIA), a mouse model of
RA, amelioration of arthritis during anti-TNF treatment
has intriguingly been shown to increase the numbers of
Th17 cells in draining lymph nodes, while reducing the
numbers of these cells in the inflamed paws [23]. Subse-
quently two small studies in patients with RA also sug-
gest that anti-TNF treatment may increase circulating
Th17 cells, but these studies did not directly investigate
the relationship of these changes to treatment response
[24, 25]. We have previously reported an increase in
peripheral blood Th17 cell numbers by fluorescence-
activated cell sorting (FACS) and an increase in IL17-
producing cells by enzyme-linked immunospot assay
(Elispot) after anti-TNF treatment in patients with anky-
losing spondylitis, psoriatic arthritis and RA [26]. In
addition, we showed that the kinetics of change in periph-
eral blood Th17 cells are the same whether or not TNF
inhibition is mediated by adalimumab (a monoclonal anti-
body) or etanercept (a TNFR-2 fusion protein) [26].
In the present study, we extend these observations to
longitudinally investigate the relationship between the
frequency of circulating Th17 cells during anti-TNF ther-
apy in patients with RA with clinical and morphological
changes, in particular synovial thickening and vascularity
as assessed by ultrasonography in response to treatment.
Methods
Study population
Patients with RA (n = 25) with an established diagnosis
according to the 1987 American College of Rheumatology
criteria [27] were recruited from Imperial College Health-
care National Health Service (NHS) Trust clinics (Table 1).
Patients were evaluated at four pre-determined protocol
visits - prior to treatment initiation and at 1, 4 and
Table 1 Changes in clinical measures of disease activity over 12 weeks on anti-TNF treatment in 25 patients with rheumatoid arthritis
Parameter Baseline Week 1 Week 4 Week 12
Mean ± SD Mean ± SD P value Mean ± SD P value Mean ± SD P value
DAS28-ESR 5.72 ± 0.84 4.47 ± 1.14 **** 4.26 ± 1.13 **** 2.87 ± 1.11 ****
DAS28-CRP 5.28 ± 0.98 3.98 ± 1.09 **** 3.85 ± 1.13 **** 2.36 ± 1.04 ****
SJC28 7.68 ± 5.36 4.42 ± 3.89 ** 4.54 ± 4.28 ** 3.00 ± 3.83 ***
TJC28 14.88 ± 8.51 8.95 ± 6.66 *** 8.76 ± 6.69 ** 4.68 ± 4.93 ***
CRP 15.74 ± 18.26 5.29 ± 6.39 *** 10.75 ± 24.15 *** 8.73 ± 16.48 ***
ESR 27.21 ± 22.67 20.50 ± 19.36 ** 19.96 ± 14.88 ** 20.45 ± 16.73 ns
Data are presented as mean ± SD. DAS28 disease activity score in 28 joints, ESR erythrocyte sedimentation rate, CRP C-reactive protein, SJC28 swollen joint count
out of 28 joints, TJC28 tender joint count out of 28 joints
Each time point on treatment was compared to baseline using Wilcoxon matched pairs test; **P < 0.001, ***P < 0.0005, ****P < 0.0001
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12 weeks after initiation of treatment with anti-TNF
agents. Inclusion criteria included active disease at base-
line as defined by the disease activity score of 28 joints
(DAS28) >5.1 on two occasions at least 1 month apart,
and failed therapy with at least two disease-modifying
anti-rheumatic drugs (DMARDs), including methotrexate.
Patients were treated with either etanercept 50 mg weekly
or adalimumab 40 mg fortnightly as determined by their
treating physician. Patients were excluded if they had pre-
viously been treated with biologic agents, had inter-
current active infection, had undergone a change in the
dose of DMARDs in the 4 weeks preceding study entry or
had received oral, intramuscular or intra-articular steroids
in the preceding 4 weeks.
Patients were defined as responders (n = 16) or non-
responders (n = 9) to anti-TNF based on whether they
achieved improvement in the DAS28 score >1.2 from
baseline to 12 weeks on treatment, based on European
League Against Rheumatism (EULAR) response criteria
[28]. Age, disease duration, medications, presence of
rheumatoid factor or anti-cyclic citrullinated peptide
(Anti-CCP) antibody positivity were obtained from re-
view of medical notes. Disease activity was assessed by
the DAS28 score on the day of sample collection and
erythrocyte sedimentation rate (ESR) and C-reactive
protein (CRP) were determined in the clinical laboratory.
Patients also underwent high frequency grey scale and
power Doppler ultrasound of 10 metacarpophalangeal
(MCP) joints to assess synovial thickening and synovial
vascularity at each visit. Subject data are summarised in
Table 1.
Peripheral blood mononuclear cell (PBMC) isolation
Peripheral venous blood was collected in glass tubes con-
taining sodium heparin and PBMC were isolated by density
gradient centrifugation using Lympholyte (Cedarlane,
Ontario, Canada). PBMC were cryopreserved at a density
of 5 − 10/106/ml in heat-inactivated fetal bovine serum
(FBS) (Gibco, Paisley, UK) containing 10% dimethyl
sulfoxide (Sigma, Gillingham, UK), placed overnight at
-80 °C in a cryogenic vessel containing isopentane and
subsequently transferred to liquid nitrogen. To minimise
intra-assay variability, all measurements at all time points
were analysed simultaneously for each patient.
Elispot assay to quantitate IL17-producing cells
PBMC from the baseline visit and weeks 4 and 12 on
treatment were thawed, washed and resuspended at
2 × 106/ml in RPMI containing 10% human AB serum
(Sigma). Cell viability by trypan blue was consistently
>95%: 2 × 105 cells were cultured in triplicate in RPMI/
10%AB serum containing 1 μg/ml anti-CD3 (OKT3
clone, eBiosciences, Hatfield, UK) for 20 hours. PHA
(1 μg/ml) or medium alone were used as positive and
negative controls respectively. Sterile multiscreen 96-well
plates (Millipore, Bedford, MA, USA) were coated with
IL17 capture antibody (R&D Systems, Abingdon, UK),
used according to manufacturer’s instructions, and incu-
bated at 4 °C for 16 hours. The stimulated cells were
transferred to the coated plates for a further 24 hours.
The plates were washed and biotinylated anti-IL17 anti-
body (R&D Systems), used according to manufacturer’s
instructions, was added for 2 hours. Streptavidin-AP
(R&D Systems), used according to manufacturer’s in-
structions, was added to the plates for 2 hours at room
temperature in the dark. BCIP/NBT solution (R&D
Systems) was added for 30 minutes to allow visualisa-
tion of coloured spots. The spots were counted using an
automated Elispot reader (AID, Strassberg, Germany).
The number of specific spot forming cells (spSFC) was de-
termined as the mean number of spots in the presence of
stimulation agent minus mean number of spots in wells
containing medium only.
Flow cytometry quantitation of CD4 + IL17-producing
cells
Thawed PBMC at a concentration 15 × 106/ml were
placed in culture medium (RPMI 1640 supplemented
with 10% FBS, 1% penicillin/streptomycin and 1% L-
glutamine, all Sigma) and stimulated for 5 hours with
phorbol myristate acetate (PMA, 50 ng/ml) and Iono-
mycin (500 ng/ml) (both Calbiochem, Nottingham, UK)
in the presence of 10 μg/ml Brefeldin A (Sigma). Cells
were incubated with Aqua-Live/dead fixable dead cell kit
(Invitrogen, Paisley, UK), used according to manufacturer’s
instructions, for 30 minutes at 4 °C and subsequently
stained with anti-CD4-FITC and anti-CD8-PerCP/Cy5.5
(BD Biosciences, Oxford, UK) for 30 minutes at 4 °C
before fixation with Cytofix (BD Biosciences). Cells were
permeabilised with phosphate-buffered saline containing
1% bovine serum albumin and 0.05% saponin (Sigma) and
stained with anti-IL17-PE (BD Biosciences) for 30 minutes.
Cells were acquired and analysed on the FACS CantoII
using FACS DIVA software (BD Biosciences). Live cells
were identified by FSC-A/FSC-W profile and negative
staining for Aqua-live/dead kit. Lymphocytes were identi-
fied by back-gating from CD8 and using the forward and
side scatter profile.
PDUS image acquisition
At each study visit, patients underwent high-frequency
grey scale and power Doppler ultrasound over the dor-
sum of 10 MCP joints in the transverse plane using the
GE Logiq9 machine with a two-dimensional M12L
transducer (GE Healthcare, Buckinghamshire, UK) per-
formed by the same sonographer (DH) to ensure
consistency. Settings on the machine were kept constant:
grey scale frequency 14 MHz, power Doppler frequency
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7.5 MHz, Gain 50, PRF 1.4 KHz, wall filter 127 Hz. To
standardise image acquisition, the hands were main-
tained in a position of rest using a splint. The timing of
scanning at each visit was within 1 hour of the baseline
visit. Images were anonymised and stored for future
analysis.
PDUS image analysis
Anonymised clips and images were analysed by the same
assessor (DH) for synovial thickening and vascularity in
the transverse plane, by a quantitative scoring method
previously described by us using a computerised image
analysis system (ImageJ, v1.42q, NIH, Bethesda, USA)
[19, 29]. Synovium was defined as an anechoic or hypoe-
choic region over the dorsum of the joint, visible in the
transverse and longitudinal planes. The synovial area
measures were made from the first technically qualified
image on high frequency grey scale ultrasound. Each
PDUS scan consisted of a 5-second movie clip and
PDUS measures were made on the image frame at the
peak of the PDUS signal. Synovial thickness area (STA)
is a count of the number of pixels with synovial hyper-
trophy within a defined region of interest. The power
Doppler area (PDA) is a count of the number of pixels
with PDUS signal within the defined region of interest.
Extra-articular digital vessels and reflection artefacts
were excluded, if present. The individual STA and PDA
scores of each MCP were summated to create a total
synovial thickening (Trans STA) and synovial vascularity
score (Trans PDA), respectively for all 10 MCPs.
Statistical analysis
The analysed parameters obtained at protocol time points
on treatment were compared to baseline using the
Wilcoxon signed rank matched-pairs test. Correlation was
analysed using Spearman rank. Data were analysed using
Prism version 5 (Graphpad Software Inc, La Jolla, USA);
p values less than 0.05 were considered significant.
Results
Patient characteristics and response to therapy
Patients with RA (n = 25, 18 female and 7 male; mean
age ± SD 57.4 ± 11.7 years; mean disease duration ± SD
10.6 ± 9.2 years) with active disease (mean DAS28 ± SD
5.72 ± 0.84) were followed longitudinally during the initial
12 weeks of treatment with anti-TNF (18 patients were
treated with etanercept and 7 patients with adalimumab).
Anti-TNF treatment led to a significant reduction in
DAS28, as early as 1 week after anti-TNF initiation in the
whole cohort, with further reduction at 4 and 12 weeks on
treatment (Table 1). There was also a significant improve-
ment in laboratory measures of disease activity, ESR and
CRP. Based on EULAR response criteria, 16 patients were
classified as good responders and 9 patients as non-
responders to anti-TNF therapy at 12 weeks.
Improvement in synovial thickening and synovial
vascularity with anti-TNF therapy
To assess variability in grey scale and PDUS image ac-
quisition, five patients were scanned twice at the same
sitting and the intra-class correlation coefficient (ICC)
for Trans STA (ICC = 0.99) and Trans PDA (ICC = 0.99)
indicated excellent agreement between the two scans
confirming the imaging technique was consistent and re-
producible. To assess within-scan intra-reader reprodu-
cibility in image analysis, 10 anonymised scans were
randomly selected and the grey scale and PDUS were re-
read in a blinded fashion and the intra-class correlation
coefficient for Trans STA (ICC = 0.91) and Trans PDA
(ICC = 0.99) indicated excellent agreement.
At baseline, quantitative measures of synovial vascularity
correlated positively with disease activity (DAS28, r = 0.59,
p = 0.01). The kinetics of change of both quantitative mea-
sures of synovial thickening and synovial vascularity did
not differ significantly between those patients treated with
etanercept and those with adalimumab and both measures
showed improvement with anti-TNF treatment, irres-
pective of type (data not shown).
The quantitative measures of synovial thickening
and synovial vascularity were both able to discriminate
between EULAR good responders and non-responders
to anti-TNF treatment (Fig. 1). Overall, in the subgroup of
anti-TNF responders there was a significant improvement
in Trans STA after 4 and 12 weeks of therapy and a
significant improvement in Trans PDA after 1, 4 and
12 weeks of treatment, whereas neither measure changed
significantly in non-responders during anti-TNF treatment
(Table 2). Representative high-frequency grey scale and
PDUS images from a EULAR good responder and non-
responder patient at baseline and after 12 weeks on treat-
ment are shown in in Fig. 1. Importantly, although in
EULAR good responders both Trans STA and Trans
PDA measures improved significantly during treatment,
these ultrasound measures exhibited different kinetics
of change, with earlier and more marked improvement
in synovial vascularity during anti-TNF treatment com-
pared to synovial thickening (Table 2).
Anti-TNF treatment increases frequency of circulating
Th17 cells
The frequency of circulating IL17-producing cells (spSFC/
106 PBMC by IL17 Elispot assay) increased significantly
12 weeks after anti-TNF initiation (median (range) spSFC/
106 360 (280–645) vs 632 (367–1167), p = 0.003) com-
pared to baseline (Fig. 2a, b). To determine the relative
proportion of CD4+ cells amongst IL17-producing cells in
the Elispot assay, PBMC depleted of CD4+ cells using
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magnetic beads were tested in three patients with RA.
Whole PBMC and a sample of PBMC from the same pa-
tients after CD4+ cell depletion were set up in the IL17
Elispot assay. The effectiveness of the depletion and purity
of the depleted fraction was verified by flow cytometry
and confirmed that the remaining CD4+ cell population
was effectively depleted of CD4+ cells (Fig. 1a, Additional
file 1: Figure S1). The depletion of CD4+ cells from the
PBMC population significantly reduced IL17 responses,
demonstrating the great majority of IL17 was produced by
CD4+ cells (Fig. 1b and c, Additional file 1: Figure S1).
Using flow cytometry we evaluated the presence of CD4+
cells co-expressing IL17 and IFNγ but consistently found
the frequency of this population to be negligible both at
baseline and during anti-TNF treatment.
Flow cytometry analysis also confirmed a significant in-
crease in the percentage of circulating CD4 + IL17+ cells
12 weeks after anti-TNF initiation compared to base-
line (median (range) %, 0.7 (0.5–0.9) vs 1.05 (0.6–1.3),
p = 0.01) (Fig. 2c and d).
Increase in circulating Th17 cells correlates with reduction
in joint inflammation
Having shown that anti-TNF treatment induces an in-
crease in circulating Th17 cells in patients with RA, we
then investigated the relationship between this increase
in circulating Th17 cells and clinical and ultrasonographic
measures of disease activity. We found significant negative
correlation between the change in numbers of IL17-
producing cells (by IL17 Elispot) from baseline to
Fig. 1 Differences between anti-TNF responders and non-responders in improvement in synovial thickening and vascularity. Representative ultrasound
images of changes in synovial thickening (a and b) and synovial vascularity (c and d) in a metacarpophalangeal joint of a good responder (a and c)
and poor responder (b and d) to anti-TNF therapy
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week 12 on treatment and the change in Trans STA
score (r = -0.39, p = 0.04) and the change in Trans
PDA score (r = -0.68, p = 0.007) from baseline to
12 weeks on treatment (Fig. 3). These negative corre-
lations suggest that the increase in frequency of circu-
lating Th17 cells occurring during anti-TNF treatment
is associated with reduction in synovial thickening
and synovial vascularity in patients with RA.
Higher frequency of circulating Th17 cells at baseline is
associated with poor anti-TNF response
We investigated whether there was a relationship between
higher frequencies of circulating Th17 cells prior to anti-
TNF initiation and ultrasonographic measures of treat-
ment response. A positive correlation was observed
between the frequency of IL17-producing cells at baseline
(by IL17 Elispot) and the change in synovial vascularity by
PDUS from baseline to week 1 on treatment (r = 0.46,
p = 0.02) (Fig. 4a). There were also strong positive cor-
relations between the frequency of circulating IL17-
producing cells at baseline and the change in synovial
thickening from baseline to week 1 (r = 0.72, p = 0.0004),
from baseline to week 4 (r = 0.51, p = 0.01) and from base-
line to week 12 on treatment (r = 0.52, p = 0.01) (Fig. 4b-d).
These relationships demonstrate that higher baseline fre-
quencies of Th17 cells are associated with a smaller
improvement, or worsening, in synovial vascularity and
synovial thickening during anti-TNF therapy. Thus they
suggest that higher baseline frequencies of Th17 cells may
be associated with a poorer anti-TNF treatment response.
Similarly, there was a positive correlation between the per-
centage of CD4 + IL17+ cells (by FACS) at baseline and the
change in synovial vascularity score from baseline to week
1 (r = 0.66, p = 0.002) (Fig. 2, Additional file 2: Figure S2).
There were also positive correlations between the percent-
ages of CD4 + IL17+ cells at baseline and the change in
synovial thickening score from baseline to week 1 (r = 0.51,
p = 0.01), from baseline to week 4 (r = 0.36, p = 0.04) and
from baseline to week 12 (r = 0.35, p = 0.05, Fig. 2,
Additional file 2: Figure S2). The consistency of the results
obtained using both Elispot and FACS adds strength to the
findings.
In view of the relationships observed between a higher
frequency of Th17 cells at baseline and a smaller im-
provement, or worsening, in synovial thickening and
vascularity during treatment, we compared the fre-
quency of circulating Th17 cells prior to anti-TNF initi-
ation between EULAR good responders and non-
responders to therapy. Anti-TNF non-responders showed
a trend towards having a higher frequency of circulating
Th17 cells at baseline compared to good responders, both
by Elispot (EULAR non-responders vs good responders
median (range) spSFC/106, 538 (280–725) vs 405
(310–540), p value not significant) and FACS (EULAR
non-responders vs good responders median (range) %,
0.9 (0.7–1.2) vs 0.7 (0.48–0.9), p value not significant).
Discussion
We conducted a longitudinal investigation of patients
with RA during the initial 12 weeks of anti-TNF treat-
ment using clinical, ultrasonographic and T cell assess-
ments to gain an understanding of immune correlates of
treatment response. This longitudinal evaluation allowed
us to identify a link between changes in circulating Th17
cells, evaluated by cellular assays, and resolving synovial
inflammation and vascularity during anti-TNF treatment.
Anti-TNF treatment led to a significant and sustained
improvement in clinical measures of disease activity and
morphological improvement in synovial thickening and
vascularity determined by grey scale and PDUS during
12 weeks of treatment. We observed strong positive
correlations between DAS28, a composite measure of
disease activity, and synovial vascularity score by PDUS,
a more objective and quantitative measure of synovitis
in the limited set of joints assessed. These findings are
in agreement with previous studies [14–16, 30–33].
There was a clear difference between anti-TNF EULAR
good responders and non-responders in the change in
Table 2 Changes in ultrasound measures of synovial thickening and synovial vascularity in treatment responders and non-responders
during 12 weeks of anti-TNF treatment
Parameter Baseline Week 1 Week 4 Week 12
Median (range) Median (range) P value Median (range) P value Median (range) P value
Total synovial thickness area score (10 MCP trans STA)


















Total synovial power Doppler area score (10 MCP trans PDA)
Responders (n = 16) 3213 (115–6772) 949 (156–2967) * 114 (17–2310) ** 76 (4.5–1075) *
Non-responders (n = 9) 25 (0–1079) 48 (0–98) ns 57 (0–169) ns 87 (12.5 − 780) ns
Values are presented as median (interquartile range). Comparison of each time point on treatment versus baseline made using Wilcoxon matched pairs test;
*p < 0.05, **p < 0.005, ns non-significant
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ultrasound measures of synovial thickening and vascularity
during anti-TNF treatment. Responders demonstrated a
significant improvement in synovial thickening and vascu-
larity after 1, 4 and 12 weeks on treatment, whereas there
were no significant changes in the non-responder group.
The ultrasound measures of synovial vascularity were better
able to discriminate between responder and non-responder
groups compared to synovial thickening, which has also
been shown by others [19, 29, 31, 34].
Synovial thickness and vascularity scores improved
during anti-TNF treatment in EULAR good responders,
but interestingly they exhibited different kinetics of change,
with synovial vascularity showing earlier and more marked
improvement compared with synovial thickening scores.
PDUS signal has been shown to reflect vascularisation of
pannus in RA and to correlate with histological changes of
synovitis and synovial membrane microvascular density
[32, 33]. One of the mechanisms of action of anti-TNF
agents is through reduction of neovascularisation and
angiogenesis of the synovial tissue by reducing expression
of vascular endothelial growth factor (VEGF) [35]. Thus,
anti-TNF appears to act rapidly to reduce synovial vascular-
ity and therefore inflammation, which is reflected by
improvement in ultrasound measures of vascularity. The
Fig. 2 Anti-TNF treatment increases frequency of circulating T helper (Th)17 cells. Change in numbers of IL17-producing peripheral blood mononuclear
cells during anti-TNF treatment determined by IL17 enzyme-linked immunospot (Elispot) assay (a) and representative IL17 Elispot experimental wells
(b). PBMC (n = 200,000) were seeded in triplicate in each experiment and stimulated with 1 mg/ml anti-CD3 antibody for 20 hours and the numbers
of cytokine-producing cells were enumerated. Change in the frequency of circulating CD4 + IL17+ cells in the peripheral blood of patients with
rheumatoid arthritis (RA) determined by flow cytometry (c) and representative dot plots (d). Bars represent median and interquartile range; *p < 0.05,
**p < 0.01 versus baseline visit (Wilcoxon matched pairs test). spSFC/106, specific spot-forming cells per million PBMC
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reduction in synovial thickness assessed by grey scale ultra-
sonography is a slower process as it is likely to represent a
decrease in swelling and inflammation of the synovium,
which is likely a combination of reduction in infiltration of
inflammatory cells in the joints, reduced expression of
inflammatory cytokines and chemokines and reduction in
synovial vascularity [36–38].
Using Elispot and intra-cellular cytokine staining, we
demonstrated an increase in circulating Th17 cells during
anti-TNF treatment in patients with RA. These results
were obtained using two different but complementary
techniques for assessing cellular immune responses and
were consistent, thus strengthening our findings. The in-
crease in circulating Th17 cells during anti-TNF treatment
has been indicated in two small studies but these have
evaluated Th17 cells using flow cytometry only, or by
measurement of IL17 production by stimulated PBMC
using ELISA at one time point on treatment [24, 25].
We found significant negative correlation between the
change in numbers of Th17 cells from baseline to 12 weeks
on treatment and the change in ultrasound scores for
synovial thickening and vascularity from baseline to
12 weeks. Thus, as the frequency of Th17 cells increases
in peripheral blood during anti-TNF treatment, there is a
corresponding improvement in synovial thickening and
vascularity. Our results suggest that the increase in Th17
cells in peripheral blood during treatment is associated
with improvement in synovial thickening and vascularity.
This is the first study to link changes in T cell im-
munopathology assessed by cellular assays with the
morphological changes in inflamed joints assessed by
PDUS during anti-TNF treatment. These correlations are
consistent with the mechanism of action of anti-TNF
agents. One of the key mechanisms of action through
which anti-TNF has been shown to lead to improvement
in arthritis is through reduction in trafficking of inflamma-
tory cells to joints through reduced synovial expression of
chemokines and adhesion molecules and also reduced
angiogenesis and synovial VEGF expression [35, 37, 38].
In patients with RA, infliximab causes a reduction in the
cellularity of inflamed synovial tissue, with significant re-
ductions in the number of intimal and sublining macro-
phages, plasma cells and T cells which parallels the rapid
reduction in swollen joints as early as 48 hours after
infliximab infusion [39]. Furthermore, a study in pa-
tients with RA demonstrated that the frequency of
Th17 cells in synovial fluid from inflamed knee joints
correlated with positive PDUS signal of the knee joint
and increased levels of synovial fluid VEGF, suggesting
that the presence of PDUS signal in the joints may
therefore be a surrogate marker for the presence of
Th17 cells [7]. Thus, the negative correlation between
the increase in peripheral blood Th17 cells during anti-
TNF treatment and the decrease in synovial thickness
and vascularity on ultrasound suggests that anti-TNF
treatment may induce redistribution of inflammatory
cells from joints, leading to improvement in joint swelling
and inflammation.
Another possible mechanism through which anti-TNF
may cause an increase in circulating Th17 cells is through
Fig. 3 Increase in circulating T helper (Th)17 cells during anti-TNF treatment correlates with improvement in joint inflammation. Negative correlation is
shown between the change in frequency of IL17-positive cells (determined by IL17 enzyme-linked immunospot (Elispot) assay) from baseline to week
12 on treatment and the change in quantitative ultrasound scores for synovial thickening (Trans STA) and vascularity (Trans PDA) from baseline to week
12 in patients with rheumatoid arthritis (RA). Correlation was tested using the Spearman’s rank method. 10 MCP Trans PDA composite transverse power
Doppler area score for synovial vascularity of ten metacarpophalangeal joints, 10 MCP Trans STA composite transverse synovial thickness area score of
ten metacarpophalangeal joints. a Synovial thickening. b Synovial vascularity
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an increase in the p40 subunit shared between IL12 and
IL23, the key cytokines involved in differentiation of Th1
and Th17 cells, respectively. In a study by our group using
the CIA mouse model of RA, anti-TNF therapy ameliorated
arthritis by decreasing numbers of Th1 and Th17 cells in
arthritic joints, but also caused an increase in Th1 and
Th17 cells in draining lymph nodes [23]. By using knockout
mice, the increase in Th1 and Th17 cells was shown to
Fig. 4 Higher frequency of T helper (Th17) cells at baseline associated with poorer response to anti-TNF treatment. Positive correlation between
the frequency of circulating IL17-producing cells (determined by IL17 enzyme-linked immunospot (Elispot) assay) at baseline and the change in
quantitative score for synovial vascularity (composite transverse synovial thickness area score of ten metacarpophalangeal joints (10 MCP Trans
PDA score) from baseline to week 1 on treatment (a) in patients with rheumatoid arthritis (RA) with presence of power Doppler signal at baseline
(n = 19). Positive correlation is shown between the frequency of circulating IL17-producing cells (determined by IL17 Elispot assay) at baseline and
the change in quantitative score for synovial thickening (10 MCP Trans STA score) from baseline to week 1 (b), from baseline to week 4 (c) and
from baseline to week 12 (d) on treatment in the whole RA cohort. Correlation was tested using Spearman’s rank method. spSFC/106 specific spot
forming cells per 106, 10 MCP Trans PDA composite transverse power Doppler area score for synovial vascularity of ten metacarpophalangeal joints
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occur through signalling via the TNFp55 receptor, which
increased expression of the p40 subunit shared between
IL12 and IL23. A similar mechanism was found to occur in
a mouse model of reactive arthritis, where Yersinia-induced
reactive arthritis in mice lacking TNFp55 receptor was as-
sociated with more severe disease. Increased levels of IL17,
IL23 and IL12p70 were found in the arthritic joints of these
mice and antibody blockade of IL17 was shown to reduce
arthritis severity. The increase in Th17 responses in the
TNFRp55-/- mice was shown to be mediated by an in-
crease in IL12/23p40 [40]. TNFα-mediated inhibition of
IL12/23p40 may also occur in human disease. A study by
our group in patients with RA treated with anti-TNF
showed that the increase in circulating Th17 cells up to
12 weeks on anti-TNF was accompanied by an increase in
IL12/23p40 production in supernatants from PBMC stimu-
lated with lipopolysaccharide (LPS) and also in the plasma
layer of whole blood stimulated with LPS [25]. Taken to-
gether, these findings suggest that anti-TNF agents may act
through several mechanisms to increase circulating Th17
cells during treatment.
Another interesting finding to emerge from this study
is that anti-TNF non-responders showed a trend towards
a higher baseline frequency of Th17 cells compared to
responders and this trend was observed using results
from both Elispot and intra-cellular cytokine staining.
Two other studies also point to an association between
higher baseline levels of IL17 or a higher frequency of
Th17 cells and poor anti-TNF treatment response in
RA; although in these studies this relationship has been
investigated using clinical measures of disease activity
only and at a single time point on treatment, rather than
longitudinally [25, 41]. We investigated this hypothesis
by exploring relationships between ultrasonographic and
T cell immunological changes during anti-TNF therapy
to determine if a higher frequency of IL17-producing
cells at baseline was associated with poor treatment re-
sponse. Indeed, we found significant correlation between
higher numbers of Th17 cells at baseline and a smaller
improvement in synovial vascularity on ultrasound at
1 week, and a smaller improvement in synovial thicken-
ing at 1, 4 and 12 weeks after anti-TNF initiation This
suggests that a higher frequency of Th17 cells at baseline
is associated with poor anti-TNF treatment response.
We have used two different but complementary tech-
niques (Elispot and intracellular cytokine staining) to assess
the frequency of Th17 cells prior to anti-TNF initiation and
using both methods, we found a significant relationship be-
tween a higher baseline frequency of Th17 cells and poor
treatment response assessed by ultrasonographic measures.
If these associations are also confirmed in larger patient co-
horts and in patients with other types of inflammatory arth-
ritis aside from RA, the characterisation of Th17 cells as a
marker of anti-TNF non-response raises the possibility of
being able to tailor biologic therapy of inflammatory arth-
ritis according to individual patient immunological profiles.
Further investigation is warranted into whether patients
with higher baseline frequencies of circulating Th17 cells
may have more IL17-driven disease and whether these pa-
tients may derive greater benefit from treatment with a
combination of anti-IL17 and anti-TNF agents.
Conclusions
The present study shows that anti-TNF treatment in-
duces an increase in circulating Th17 cells in patients
with RA and this increase correlates with reduction in
synovial thickening and vascularity. This is the first
study to link increases in circulating Th17 cell numbers
and IL17 production with resolution of ultrasonographic
features of synovitis during anti-TNF treatment. We also
showed that higher baseline frequencies of Th17 cells
were associated with poorer anti-TNF treatment re-
sponse. These observations raise the possibility that dual
inhibition of IL17 and TNF may be a means to further
advance therapeutic outcomes [42]. Fischer et al. have
reported synergistic effects of TNF and IL-17 blockade
in mice transgenic for human TNF and combined anti-
TNF and IL-17 treatment had a superior effect on bone
homeostasis than anti-TNF alone or anti-IL-17 alone [43].
Additional files
Additional file 1: Figure S1. Depletion of CD4+ cells attenuates IL-17
responses in the Elispot assay. Cells were stained with CD4-PE pre and
post magnetic labelling to assess effectiveness of CD4+ depletion by flow
cytometry (A and B). Whole PBMCs prior to depletion contain CD4+ T
cells (A) whilst after depletion of CD4+ T cells with magnetic beads, there
are virtually no CD4+ T cells present in this representative patient (B). The
frequency of IL17-producing peripheral blood mononuclear cells is markedly
attenuated when CD4+ cells are depleted from the PBMC population (C).
The effects of depletion are shown in three representative patients. PBMC
(n = 200,000) prior to and after the depletion from each patient were set up
in the IL17 Elispot assay and stimulated with 1 mg/ml anti-CD3 antibody
(OKT3 clone). Results are expressed as number of IL17 specific spot forming
cells per million PBMC. Representative experimental wells of the IL17 Elispot
assay from one patient are shown demonstrating that after depletion of
CD4+ cells the number of IL17-positive spots per well is attenuated (D).
Each spot represents one cytokine-producing cell. The numbers under each
well indicate the total number of IL17-positive spots in that well. spSFC/106
specific spot-forming cells per million PBMC. (DOCX 127 kb)
Additional file 2: Figure S2. Higher frequency of Th17 cells at baseline
associated with poorer response to anti-TNF treatment. Positive correlations
are shown between percentages of circulating CD4 + IL17+ cells (determined
by intracellular cytokine staining using flow cytometry) at baseline and the
change in quantitative score for synovial vascularity (10 MCP Trans PDA score)
from baseline to week 1 on treatment (A) in patients with RA with presence
of power Doppler signal at baseline (n = 19). Also positive correlations are
shown between the percentages of circulating CD4 + IL17+ cells at baseline
and the change in quantitative score for synovial thickening (10 MCP Trans
STA score) from baseline to week 1 (B), from baseline to week 4 (C) and
from baseline to week 12 (D) on treatment in the whole RA cohort.
Correlations was tested using Spearman’s rank method. 10 MCP Trans
PDA composite transverse power Doppler area score for synovial vascularity of
ten metacarpophalangeal joints, 10 MCP Trans STA composite transverse
synovial thickness area score of ten metacarpophalangeal joints. (DOCX 51 kb)
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